eDiagnosis(SZ:002932)2025-06-12 11:05Group 1: Company Performance and Strategy - The company has faced poor performance in both revenue and stock price over the past two years, with significant cash reserves not being effectively utilized [2][3] - The company aims to achieve a market value of 100 billion CNY and plans to enhance operational efficiency, seek investment mergers, and maintain cash dividends as part of its 2025 valuation enhancement plan [4] - The company is focusing on core technology advantages and exploring new growth points in in vitro diagnostic reagents and high-end medical equipment [5] Group 2: Investment and Mergers - The company has established a joint venture with Junlian Capital to focus on investment and mergers in innovative healthcare [3] - There are plans to collaborate with excellent fund managers and investment institutions to create industry funds supporting diversified business development [3] - The company is actively evaluating investment and merger opportunities that align with its strategic direction to enhance market share [5] Group 3: Financial Management - The company is committed to improving accounts receivable management, which has shown progress with a continuous decrease in accounts receivable balance [5] - A share repurchase plan was completed in March 2025, initiated in 2024, to address the stock price being below net asset value [5] Group 4: Product Development - The company has launched a new respiratory virus nucleic acid detection kit, which received medical device registration in May 2025, although sales have been limited so far [6] - The focus remains on enhancing the product line in pathogen diagnosis, cardiovascular disease diagnosis, and infectious disease diagnosis to improve market share [3]